[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-type-2-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-type-2-diabetes-mellitus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,83,125,151,182,211,237,259,281,303,333,363],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642036","endoscopic-sleeve-gastroplasty-plus-duodenal-pulsendo-for-obese-t2dm-100642036",false,"NCT07660445","Endoscopic Sleeve Gastroplasty Plus Duodenal pulsENDO for Obese T2DM","Integrating Duodenal Recellularization Via Electroporation Therapy and Endoscopic Sleeve Gastroplasty as a Novel Approach to Managing Diabesity (DRAGON Study)","DRAGON","Inclusion Criteria:\n\n* BMI \\>\u002F= 27kg\u002Fm2\n* Known T2DM\n* Individualized Metabolic Surgery (IMS) score 25-115\n* HbA1c \\\u003C11% (subjects on oral glucose lowering drug(s) or HbA1c \\\u003C8% (subjects on insulin)\n\nExclusion Criteria:\n\n* Previous treatment with ReCET, ESG or similar procedure\n* Previous GI surgery that could preclude the ability to perform ReCET or ESG, or acute gastric and duodenal pathology that increased the risk of ReCET or ESG\n* Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Patients with cirrhosis due to causes other than MASLD\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate","ALL","18 Years","70 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is designed to evaluate the efficacy, safety, and mechanisms of combining ESG and pulsENDO procedure in obese patients with T2DM",[28],"Obesity Type 2 Diabetes Mellitus","RECRUITING","2026-06-20",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":22},"2026-08-01",{"date":37,"type":22},"2031-07-31",{"name":39,"class":40},"Chinese University of Hong Kong","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":41},"100642489","dash-obesity-explainable-ai-for-family-centric-personalized-weight-control-in-adolescents-and-young-adults-with-obesity-and-chronic-conditions-100642489","NCT07638345","DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions","US-based Clinical Sub-study of DASH-Obesity: Explainable AI for Family-Centric Transdiagnostic Personalized Weight Control Across Multiple Conditions","DASH-Obesity","Inclusion Criteria:\n\n* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.\n* The caregiver is actively involved in the management of the adolescent's or young adult's condition.\n* The adolescent or young adult must meet one of the following criteria:\n* T1D and normal weight (BMI between the 10th and 85th percentile), or\n* T1D and overweight\u002Fobesity (BMI ≥85th percentile), or\n* Asthma and overweight\u002Fobesity (BMI ≥85th percentile).\n* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).\n* Access to a smartphone or internet-enabled device compatible with the study application.\n* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.\n* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.\n\nExclusion Criteria:\n\n* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.\n* Current participation in another obesity- or chronic disease-related digital health intervention study.\n* Inability or unwillingness to comply with study procedures.\n* Refusal or inability to provide informed consent.",true,{"count":52,"type":22},280,[25],"This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight\u002Fobesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.",[56,57,58,28,59,60],"Type 1 Diabetes","T1D","Obesity & Overweight","Asthma Acute","Asthma (Diagnosis)",[62,56,63,64,65,66,67,68,69,70,71,72],"Pediatric Obesity","Asthma","Overweight","Digital Health","Artificial Intelligence","Explainable AI","Caregiver Burden","Quality of Life","Mental Well-being","Wearable Devices","Family-Centered Care","2026-06-19",{"date":75,"type":33},"2026-06-23",{"date":77,"type":33},"2025-10-30",{"date":79,"type":22},"2026-09",{"name":81,"class":82},"Adhera Health, Inc.","INDUSTRY",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":95,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100641243","automated-passive-case-finding-for-advanced-liver-fibrosis-in-masld-the-liverseek-programme-100641243","NCT07658755","Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme","Towards Universal Screening for Metabolic Dysfunction-Associated Liver Fibrosis in Primary Care: Evaluation of a Single-Step, Laboratory Informatión System-Driven Automated Case-Finding Strategy (LiverSeek)","LiverSeek","Inclusion Criteria:\n\n1. Age between 50 and 75 years (inclusive)\n2. Routine blood test processed in the Clinical Biochemistry Laboratory of Hospital General Universitario Gregorio Marañón, ordered by a primary care physician in one of the 11 affiliated SERMAS primary care centres\n3. Presence of at least one of the following metabolic risk factor combinations:\n\n   * ALT above the upper limit of normal AND HbA1c ≥6.5%\n   * ALT above the upper limit of normal AND BMI \\>30 kg\u002Fm²\n   * BMI \\>30 kg\u002Fm² AND HbA1c ≥6.5%\n\nExclusion Criteria:\n\n1. Age \\\u003C50 years or \\>75 years\n2. Known pre-existing liver disease (significant or advanced fibrosis, cirrhosis, hepatocellular carcinoma, prior liver transplantation)\n3. Prior fibrosis assessment within the preceding 12 months.","50 Years","75 Years",{"count":94,"type":22},3000,"24 Months","OBSERVATIONAL","LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care. The programme operates through the Laboratory Information System (LIS; Modulab\u002FBiwer Analytics) of the Clinical Biochemistry Laboratory at Hospital General Universitario Gregorio Marañón (HGUGM), covering approximately 350,000 inhabitants across 11 peri-urban primary care centres affiliated to SERMAS (Servicio Madrileño de Salud) in Madrid, Spain.\n\nWhen a high-risk patient (age 50-75 years with ≥1 of: ALT above ULN + HbA1c ≥6.5%; ALT above ULN + BMI \\>30; BMI \\>30 + HbA1c ≥6.5%) undergoes a routine blood test in primary care, the LIS automatically calculates FIB-4. If FIB-4 \\>1.30, the system reflexively orders ELF and MASEF from the same serum sample, without any action required from the primary care clinician. Patients with a positive second-step NIT (ELF ≥9.8 or MASEF ≥0.33) receive an automatic alert directing them to the Hepatology Advanced Practice Nurse for VCTE (FibroScan) and clinical evaluation.\n\nThe primary objective is to evaluate the prevalence of hepatic fibrosis in the high-risk population using this single-step automated strategy. Secondary objectives include head-to-head diagnostic comparison of FIB-4+ELF vs FIB-4+MASEF vs FIB-4+FAST for histologically-confirmed endpoints (significant fibrosis ≥F2, advanced fibrosis ≥F3, at-risk MASH), evaluation of the Liver Risk Score, and a health-economic analysis. A sub-study evaluates a nurse-led structured lifestyle intervention in NIT-positive patients.",[99,100,101,102,103,28],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Fibrosis","Non-alcoholic Fatty Liver Disease NAFLD","Type 2 Diabetes Mellitus","Obesity",[105,106,107,108,109,110,111,112,113,114,115],"MASLD","MAFLD","NAFLD","liver fibrosis","FIB-4","ELF","MASEF","screening","passive screening","advanced practice nurse","lifestyle intervention","2026-06-14",{"date":118,"type":33},"2026-06-22",{"date":120,"type":33},"2024-10-01",{"date":122,"type":22},"2027-09-01",{"name":124,"class":40},"Hospital General Universitario Gregorio Marañon",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100632801","dietary-insights-and-nutritional-education-in-adults-on-glp-1-therapy-100632801","NCT07518407","Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy","DINE-GLP1","Inclusion Criteria:\n\n* • Age between 18 and 65 years.\n\n  * BMI between 30 - 49.9 kg\u002Fm2 and\u002For diagnosed with type 2 diabetes.\n  * Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks.\n  * Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery.\n  * Residing anywhere in the United States.\n  * Must be willing and able to reduce caloric intake.\n  * Be free of major health or psychiatric diseases, drug, or alcohol dependency.\n  * Willing to sign informed consent.\n\nExclusion Criteria:\n\n* • Presence of type 1 diabetes mellitus\n\n  * Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months.\n  * Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes.\n  * Pregnancy, breastfeeding, or plans to become pregnant during the study period.\n  * Current use of another investigational weight loss device or medication.\n  * Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff.\n  * Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification.\n  * Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months.\n  * Substance use disorder or alcohol dependency within the past 12 months.\n  * Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures.\n  * Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.","65 Years",{"count":134,"type":22},50,[25],"This pilot study will evaluate the feasibility, acceptability, and perceived usefulness of the SWITCH mobile nutrition behavioral intervention among adults receiving GLP-1 receptor agonist therapy for obesity and\u002For type 2 diabetes. Participants will complete baseline assessments, receive a 6-week app-based nutrition intervention consisting of daily dietary self-monitoring and weekly learning modules, and complete follow-up assessments and a structured interview.",[28,103],[139,140,141],"GLP-1 Therapy","Nutritional support","Weight loss therapy","2026-06-09",{"date":144,"type":33},"2026-06-12",{"date":146,"type":33},"2026-04-06",{"date":148,"type":22},"2027-04-01",{"name":150,"class":40},"University of South Carolina",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100642861","hydration-intervention-to-decrease-side-effects-associated-with-glp---1-ra-therapy-100642861","NCT07641361","Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy","Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications","Inclusion Criteria:\n\n* Adults aged 18-60\n* Recently prescribed a GLP-1RA (within one week of prescription)\n* Fluent in English\n* Willing to complete the study protocol\n\nExclusion Criteria:\n\n* Children and adults \\> 60 years of age\n* Those not taking a GLP-1RA\n* Those who have been on a GLP-1RA longer than one week\n* Not fluent in English\n* Those who are pregnant or planning on becoming pregnant during the duration of the study\n* Unwilling to comply with study protocol\n* People with cardiac implants","60 Years",{"count":160,"type":22},30,[25],"This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.",[58,164,165,28,166],"Type 2 Diabetes","Type 2 Diabetes (Adult Onset)","Dehydration",[168,169,170,166,171,172],"Hydration","GLP - 1 RA","GLP - 1 RA therapy","Hydration biomarkers","GLP - 1 RA side effects","2026-06-08",{"date":175,"type":33},"2026-06-11",{"date":177,"type":22},"2026-06-15",{"date":179,"type":22},"2027-02-01",{"name":181,"class":40},"State University of New York at Buffalo",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":41},"100643668","eating-behaviour-before-during-and-after-obesity-medication-100643668","NCT07636395","Eating Behaviour Before, During, and After Obesity Medication","Qualitative and Quantitative Measures of Eating Behaviours in Humans Taking Obesity Medications Before, During, and After.","Inclusion Criteria:\n\nSigned informed consent prior to any study-related procedure Age 16-80 years-old BMI range \\> 27 kg\u002Fm2 Receiving obesity medication as part of usual care.\n\nExclusion Criteria:\n\n* Substance abuse\n* Pregnancy\n* Regular use, for more than three times a week for the last 2 months and\u002For 7 days prior to inclusion, of medications which according to the principal investigator can interfere with the study.\n* After being included in the study, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis.\n* Patients that have had bariatric surgery.","16 Years","80 Years",{"count":160,"type":22},"This study will examine how eating behaviour changes during the first 18 months of treatment with obesity medications in patients attending the St Vincent's Healthcare Group obesity service. Obesity is increasingly understood as a chronic, relapsing, multifactorial disease that requires long-term management rather than short-term advice alone. Newer anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists and related therapies, have improved weight-loss outcomes and altered the experience of hunger, fullness, food reward, and meal size for many patients. However, while weight reduction is well described in the literature, less is known about how patients themselves experience eating behaviour over time as treatment progresses from initiation to active weight loss and then towards weight maintenance. This study is designed to address that gap by exploring the lived experience of appetite and food-related behaviour across clinically meaningful stages of treatment. The study will use a longitudinal mixed-methods design. Thirty participants aged 16 to 80 years with a body mass index above 27 kg\u002Fm2 who are commencing weight-loss medication as part of routine care will be recruited. The sample size includes an allowance for a modest dropout rate over the study period. Participants will be followed at four time points: baseline, approximately 3 months after treatment initiation, around 12 months, and at 18 months, with a visit window of plus or minus 13 days. These time points were selected to reflect distinct phases of treatment. Baseline will capture pre-treatment or very early-treatment experience. Three months is expected to reflect a period of early therapeutic response, when medication effects on appetite may be most noticeable. Twelve months is likely to represent a later phase, when weight loss may be slowing and some patients may be approaching their lowest weight. Eighteen months is intended to capture maintenance or stabilisation, when behavioural changes may differ from those seen earlier in treatment. Data collection will include both questionnaires and semi-structured telephone interviews. The questionnaire component will measure key aspects of eating behaviour, including hunger, fullness, food thoughts, portion size, and palatability. Repeated administration at each study time point will allow changes in these behaviours to be tracked over time. The interview component will provide a richer understanding of how participants describe and interpret their experiences. All interviews will be conducted by one co-investigator using the same core interview guide to ensure consistency. Open-ended questions will allow participants to describe changes in appetite, eating patterns, cravings, meal satisfaction, food preferences, and daily routines in their own words, while additional probing may be used to clarify how these experiences evolve through treatment. Interviews are expected to last 15 to 45 minutes, will be audio-recorded with verbal confirmation, and transcribed for analysis. The central research question is how hunger, fullness, food thoughts, portion size, and food palatability change over time during treatment with obesity medications. The hypothesis is that appetitive and consummatory behaviours will decrease from baseline to an early low point, particularly around 3 months, and may then gradually rise again as treatment continues, before stabilising during a later maintenance phase. This pattern would reflect the possibility that the strongest appetite-suppressing effects occur early, followed by behavioural and physiological adaptation over time. At the same time, the study recognises that patients may not all follow the same course, and individual variation will be an important part of the analysis. Quantitative data will be used to describe behavioural trends across time points, while qualitative data will be analysed thematically to identify recurring experiences, challenges, and adaptations. Integrating these two forms of data will strengthen the study by linking measurable change with patient perspective. The study is expected to provide clinically useful insight into how anti-obesity medications influence the lived experience of eating, and how this may change between the active weight-loss phase and maintenance. By focusing on patient-reported hunger, satiety, food preoccupation, portion size, and palatability, the research may help clinicians better understand when patients need additional support, how expectations can be managed, and what aspects of treatment are most important for long-term success. The findings may also contribute to more personalised obesity care by highlighting the behavioural dimensions of treatment that are not captured by weight change alone.",[28,58],[195,196,197,198,199,200,201,202],"Weight loss","medications","hunger","fullness","food thoughts","palatability","portion size","food noise","2026-06-02",{"date":142,"type":33},{"date":206,"type":22},"2026-05-25",{"date":208,"type":22},"2026-10-25",{"name":210,"class":40},"University College Dublin",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":41},"100638925","fecal-microbiota-transplantation-fmt-combined-with-calorie-restricted-diet-and-semaglutide-in-patients-with-obesity-and-type-2-diabetes-100638925","NCT07599046","Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes","Effects of Comprehensive Intervention With Fecal Microbiota Transplantation Versus Conventional Treatment on Body Weight and Metabolism in Patients With Obesity Complicated by Type 2 Diabetes Mellitus: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-60 years;\n2. Body mass index (BMI) ≥30 kg\u002Fm² and \\\u003C40 kg\u002Fm²;\n3. Duration of type 2 diabetes mellitus \\\u003C1 year;\n4. Non-smoker or smoking cessation \\>3 months;\n5. Voluntary signed informed consent with commitment to complete the entire study.\n\nExclusion Criteria:\n\n1. Complicated with severe hepatic or renal insufficiency (alanine aminotransferase\u002Faspartate aminotransferase \\[ALT\u002FAST\\] \\>3 times the upper limit of normal, or estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²);\n2. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other organic intestinal diseases; autoimmune diseases, malignancies, or active infections;\n3. Medication and intervention exclusions: Use of α-glucosidase inhibitors, antibiotics, proton pump inhibitors (PPIs), or probiotics\u002Fprebiotics within the past 3 months; bariatric surgery within the past 6 months; long-term use of immunosuppressants or glucocorticoids;\n4. Others: Pregnant or lactating women; currently participating in other clinical trials.",{"count":21,"type":22},[25],"Investigation of the efficacy of fecal microbiota transplantation added to calorie-restricted diet and semaglutide versus calorie-restricted diet and semaglutide alone for weight loss and metabolic improvement in patients with moderate to severe obesity and type 2 diabetes mellitus.",[28],[223,103,224,225,226],"Type 2 diabetes mellitus","Fecal microbiota transplantation","Calorie-restricted diet","Semaglutide","NOT_YET_RECRUITING","2026-05-13",{"date":230,"type":33},"2026-05-20",{"date":232,"type":22},"2026-04-30",{"date":234,"type":22},"2029-12-30",{"name":236,"class":40},"Eighth Affiliated Hospital, Sun Yat-sen University",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":243,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":41},"100634641","the-role-of-autoantibodies-against-g-protein-coupled-receptors-in-obesity-100634641","NCT07542327","The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity","Inclusion Criteria:\n\n* Inhabitant in the Region of Southern Denmark\n* BMI above 30kg\u002Fm2\n* age between 18 and 60 years.\n\nExclusion Criteria:\n\n* individuals previously treated with GLP-1RA medication for any indication\n* Individuals who have previously undergone bariatric surgery\n* Individuals with type 1 diabetes",{"count":244,"type":22},160,"The purpose of this study is to explore if GPCR-autoantibodies:\n\n1. are pressent in people living with obesity, and are associated with degree of obesity\n2. if it is associated with obesity related diseases",[103,58,28,247],"Obesity and Obesity-related Medical Conditions",[103,249,250],"obesity-related medical conditions","GPCR- autoantibodies","2026-04-21",{"date":253,"type":33},"2026-04-24",{"date":255,"type":22},"2026-09-01",{"date":122,"type":22},{"name":258,"class":40},"Claus Bogh Juhl",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":41},"100633311","chinese-overweight-or-obesity-real-world-registry-study-100633311","NCT07525037","Chinese, Overweight or Obesity, Real-World Registry Study","Chinese Registry of Overweight or Obesity, a Multicenter Real-World Registry Study on Clinical Management - CROWN Study","Inclusion Criteria:\n\nAccording to local regulations, the subjects included in the study should meet the following criteria:\n\n1. Male or female patients aged 18 years or above\n2. Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg\u002Fm²\n3. Willing and able to use weight management apps\n4. Willing and able to provide a written informed consent for participating in the study\n5. Patients who meet the instructions for weight loss medication and have no contraindications to non-pharmacological treatments -\n\nExclusion Criteria:\n\n1. Having life-threatening comorbidities, with an expected lifespan of less than one year.\n2. Participating in an interventional trial that requires informed consent.\n3. Engaging in other organized weight loss programs or other clinical trials.\n4. Researchers identify any situation that may endanger the safety or compliance of the subjects.\n\n   \\-",{"count":267,"type":22},10000,"This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver\u002Frenal function, electrolytes, thyroid function panel \\[3 items\\], urine albumin\u002Fcreatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.",[28],[271,28],"Real world study","2026-04-10",{"date":274,"type":33},"2026-04-13",{"date":276,"type":22},"2026-05-30",{"date":278,"type":22},"2027-12",{"name":280,"class":40},"Chinese PLA General Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":130,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":288,"studyType":96,"phases":4,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},"100617035","dietary-insights-and-nutrition-experiences-in-adults-on-glp-1-therapy---a-study-on-diet-quality-changes-in-adults-on-glp-1-therapy-100617035","NCT07313384","Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication\n* Has regular access to a smartphone and internet to complete short surveys and food recalls online\n* Willing to sign informed consent.\n\nExclusion Criteria:\n\n* Already began the GLP-1 medication\n* Have medical concerns making participation unsafe",{"count":134,"type":22},"12 Weeks","The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.",[28,291],"Obesity (Disorder)",[139,293,103,141],"Nutrition Support","2026-02-17",{"date":296,"type":33},"2026-02-19",{"date":298,"type":33},"2026-02-11",{"date":300,"type":22},"2026-12-01",{"name":150,"class":40},2,{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":332},"100625057","multicentric-approval-study-trans-duodenal-barrier-for-typ-2-diabetes-with-obesity-100625057","NCT07417683","Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity","Leistung Und Sicherheit Des Trans-Duodenal Barrier (LuST)","LuST","Inclusion Criteria:\n\n* Obese patients with type 2 diabetes mellitus,\n* Age ≥ 18 years,\n* The patient is able to understand the nature, significance, and scope of the clinical trial (MPDG §28),\n* The patient has been informed and all written consents from the patient are available.\n\nExclusion Criteria:\n\n* The patient is mentally incapable of understanding the nature, objectives, or possible consequences of the clinical trial.\n* The patient is unwilling or unable to follow postoperative instructions.\n* The patient has been placed in an institution by court order or official order (MPDG §27).\n* The patient lives more than 100 km from the treatment site.\n* Pregnancy.\n* The patient is participating in another clinical trial in the field of diabetes management or metabolic syndrome.",{"count":312,"type":22},126,[25],"Approval study Trans-Duodenal Barrier The goal of this clinical trial is to determin the safety and performance of the newly developed Trans-Duodenal Barrier in adult Tryp 2 diabetic and obese patients.\n\nThe Trans-Duodenal Barrier is an endoscopic implant which can be placed to the gastric outlet and the upper small bowel by interventional endoscopy. It consists of a 60 cm long foil tube , a transpyloric shaft and and two ringlike balloons to fix it at the pylorus. It will be removed after 6 months via gastroscopy.\n\nThe main questions it aims to answer are:\n\n* Does the Trans-Duodenal Barrier lower the HbA1c of the participants ?\n* How frequent are adverse side effects related to the device?\n* How much ist the excessive wight loss of treated patients ?\n* Show patients with Metabolic assiociated Hepatosteatitis (MASH) improvements in liver elasticity (elastography) ? Researchers implant the Trans-Duodenal Barrier to enclosed patients and follow up them till 4 weeks after explantation.\n\nParticipants will:\n\n* Get the Trans-Duodenal Barrier as an implant for 6 moths\n* Visit the clinic 3 times in the implant period and once for explant.\n* Receive a telefon interview 4 weeks after explant",[316,103,28,317],"Typ 2 Diabetes","MASH",[319,320,321,322],"gastroduodenal liner","endoscopic implant","wight management","glycemic control","2026-02-10",{"date":325,"type":33},"2026-02-18",{"date":327,"type":22},"2026-03",{"date":329,"type":22},"2028-04",{"name":331,"class":82},"Trans-Duodenal Concepts GmbH",8,{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":341,"targetDuration":342,"studyType":96,"phases":4,"briefSummary":343,"conditions":344,"keywords":348,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100618818","endocare-screen-metabolic-liver-dysfunction-screening-study-100618818","NCT07336563","ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","Development of a Database of Metabolic Cases and Prevalence of Metabolic Liver Dysfunction (MAFLD\u002FMASLD) in Individuals With Metabolic Syndrome Characteristics - Screening Study (ENDOCARE - SCREEN)","ENDOCARE-SCREE","Inclusion Criteria:\n\n* Age 18-75 years.\n* Overweight or obesity (BMI ≥ 25 kg\u002Fm²) and\u002For increased waist circumference and\u002For at least one metabolic risk factor (e.g., hypertension, dyslipidemia, impaired fasting glucose\u002Fprediabetes\u002Ftype 2 diabetes), as applicable per screening program.\n* Participation in the ENDOCARE screening program.\n* Ability to provide written informed consent, including consent for processing health-related data\n\nExclusion Criteria:\n\n* Inability to provide informed consent (e.g., significant cognitive impairment, acute severe psychiatric disorder, language barrier).\n* Pregnancy or breastfeeding.\n* Known advanced liver diseases at baseline (participants may be excluded from primary analyses and\u002For described separately, per statistical analysis plan).\n* Refusal of key screening procedures (e.g., blood sampling or liver ultrasound) preventing determination of liver status.\n* Refusal of data processing under General Data Protection Regulation (GDPR) requirements.",{"count":267,"type":22},"6 Months","The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease (MASLD\u002FMAFLD) in adults with components of metabolic syndrome. Up to 10,000 participants aged ≥18 years with overweight, obesity, or metabolic risk factors will undergo standardized screening including a health questionnaire, anthropometric measurements, blood pressure assessment, laboratory testing, and liver ultrasound. The study aims to generate a comprehensive metabolic-hepatic dataset integrating clinical, laboratory, imaging, and lifestyle data. Collected data will be used to identify metabolic and behavioral risk factors for MASLD, characterize disease phenotypes, and support the development of predictive models. The ENDOCARE-SCREEN study will also serve as a qualification platform for selecting eligible participants for a subsequent interventional randomized controlled trial (ENDOCARE-SUPPORT). The study involves minimal risk procedures routinely used in clinical practice and follows ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.",[345,346,58,28,347],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) \u002F Nonalcoholic Steatohepatitis (NASH)","Metabolic Syndrome","Insulin Resistance Syndrome",[105,106,349,350,351,352,353],"Metabolic syndrome","Liver steatosis","Screening","Ultrasound","Metabolic health","2026-01-13",{"date":356,"type":33},"2026-01-15",{"date":358,"type":22},"2026-01-05",{"date":360,"type":22},"2026-10-31",{"name":362,"class":40},"Jarosław Drobnik",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":4},"100602809","cgm-use-in-non-insulin-patients-with-dm2-100602809","NCT07128342","CGM Use in Non-insulin Patients With DM2","Use of Continuous Glucose Monitoring in Veterans With Uncontrolled Diabetes Managed Without Insulin Therapy","CGM-DWI","Inclusion Criteria:\n\n* Successfully enrolled and ready to begin the VDOP program not on insulin therapy\n* Type 2 diabetes by clinical history\n* HbA1C between 8.0-12.0% inclusive within 3 months of enrollment\n* Assessment by clinician that patient is willing to and able to wear a CGM device\n* Stable diabetes medication regimen during the 3 months prior to entry\n\nExclusion Criteria:\n\n* Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy\n* Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study\n* Patients with end stage renal disease (ESRD) on dialysis\n* Anticipated acute uses of glucocorticoids (oral, injectable, or IV)\n* Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration\n* Known or suspected significant allergy to use the Dexcom sensors\n* Planning or currently enrolled on different weight program different from MOVE!\n* Participating other clinical trials",{"count":372,"type":22},100,[25],"The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications, and more recently, as over the counter versions for patients with and or without diabetes who want to better understand how diet and exercise may impact blood sugar levels. However robust evidence supporting that CGM is significantly superior to traditional home fingerstick blood glucose monitoring (FSBGM) in this population is lacking. Thus, Medicare and VHA only authorize use of CGM for patients with diabetes who require daily insulin therapy , unless they meet special criteria such as having hypoglycemia or inability to monitor glucose via traditional FSBGM.\n\nObjectives Primary Study Aim: Among veterans with uncontrolled diabetes not requiring insulin therapy who are participating in an intensive multidisciplinary program to improve diabetes control (VDOP), to assess whether use of a CGM compared to use of traditional FSBGM results in greater change in hemoglobin A1c upon VDOP completion and up to 12 months.\n\nSecondary study aims: To assess whether use of CGM in this population leads to greater improvement in diet, physical activity, and weight loss upon VDOP completion and up to 12 months.\n\nHypothesis\n\nThe use of a CGM by Veterans with T2DM who do not use insulin will help them improve their diabetes self - management (diet, physical activity, weight) and glycemic control more so than those using traditional fingerstick glucose monitoring.\n\nMethods\n\nThis will be a prospective \"open label\" randomized controlled trial where participants will be randomly assigned to CGM (intervention group) or FSBGM (control group) during their participation in VDOP.\n\nRelevance to Veterans and VA mission\n\nMost Veterans with T2DM do not use insulin. It is important for both, these Veterans and the VA, to learn whether this more costly and somewhat burdensome technology supports improvement in diabetes self-management",[376,377,28,378],"Diabetes","Type 2 Diabetes (T2DM)","Non Insulin Dependent Diabetes Mellitus","2025-08-12",{"date":381,"type":33},"2025-08-18",{"date":383,"type":22},"2025-11-01",{"date":385,"type":22},"2028-11",{"name":387,"class":388},"Milwaukee VA Medical Center","FED"]